[Is follow-up of infectious diseases unprofitable?].
von Uexküll
N
N
D002690:Chlamydia Infections / Q000150:complications / Q000188:drug therapy / Q000191:economics*; D003362:Cost-Benefit Analysis; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007348:Insurance, Health / Q000191:economics; D013548:Sweden
Ar uppföljning av smittfarlig sjukdom "olönsam"?